| Chemical Properties | Back Directory | [Boiling point ]
663.122±65.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.202±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [pka]
7.818±0.50(predicted) |
| Hazard Information | Back Directory | [Uses]
IDH1 Inhibitor 9 (compound 11S) is a potent IDH1 inhibitor with IC50 values of 124.4, 95.7 nM for IDH1 R132H, IDH1 R132C, respectively. IDH1 Inhibitor 9 induces apoptosis and cell cycle arrest at the S phase. IDH1 Inhibitor 9 shows anti-tumor activity[1]. | [in vivo]
IDH1 Inhibitor 9 (20, 40 mg/kg; i.p.; every 2 days for 8 days) shows anti-tumor activity for IDH1 mutant cancer model[1].
Pharmacokinetic Parameters (SD rats)[1].
| Parameters | iv (0.5 mg/kg) | po (5 mg/kg) | | T1/2 (h) | 1.46 ± 0.12 | 2.13 ± 0.18 | | Tmax (h) | 0.03 ± 0.00 | 0.19 ± 0.00 | | Cmax (ng/mL) | 766.5 ± 143.1 | 478 ± 76 | | AUC(0-t) (hr* ng/mL) | 236 ± 283.0 | 369.7 ± 93.2 | | CL (mL/h/kg) | 1637 ± 212 | 10103 ± 3310 | | F % | - | 16.8 ± 4.7 |
| Animal Model: | 4-5 weeks, Female nude mice (HT-1080 xenograft mouse model)[1] | | Dosage: | 20, 40 mg/kg | | Administration: | I.p.; every 2 days for 8 days | | Result: | Suppressed tumor growth without evident loss in body weight. |
| [IC 50]
R132H IDH1: 124.4 nM (IC50); R132C IDH1: 95.7 nM (IC50) | [References]
[1] Xu T, et al. Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study. Eur J Med Chem. 2024 Jun 17;275:116610. DOI:10.1016/j.ejmech.2024.116610 |
|
|